1. Acyclovir's exceptional tolerability is attributed to the magnitude of selective concentration of its active form in infected cells. Viral thymidine kinase phosphorylates acyclovir far more efficiently than host kinases convert the unphosphorylated drug. Approximately what magnitude of intracellular concentration gradient of active drug does this produce between infected and uninfected cells?
A) Roughly 2- to 3-fold
B) Roughly 5- to 10-fold
C) Roughly 40- to 100-fold
D) No measurable gradient
E) Roughly 1000- to 5000-fold
ANSWER: C
Rationale:
Viral thymidine kinase (TK) converts acyclovir to acyclovir monophosphate far more efficiently than cellular kinases phosphorylate the unphosphorylated drug, creating an intracellular concentration gradient of active drug on the order of 40- to 100-fold in infected versus uninfected cells. This large differential is the basis for acyclovir's selectivity and its excellent tolerability even at high intravenous doses.
Option A: Option A is incorrect: a gradient of only 2- to 3-fold would not confer the marked selectivity acyclovir shows; the actual differential is far larger.
Option B: Option B is incorrect: 5- to 10-fold understates the gradient; that range is closer to the modest selectivity index seen with ganciclovir for CMV-infected cells.
Option D: Option D is incorrect: there is a substantial gradient — its existence is precisely why acyclovir is selective.
Option E: Option E is incorrect: the gradient is large but not on the order of thousands-fold; the established figure is roughly 40- to 100-fold.
2. Acyclovir is active against HSV-1, HSV-2, and VZV, but its potency varies across these viruses, which is reflected in clinical dosing. Why is oral acyclovir dosed substantially higher for varicella and zoster (for example, 800 mg five times daily) than for herpes simplex virus infections (for example, 400 mg three times daily)?
A) VZV is approximately 10-fold less susceptible to acyclovir than HSV
B) VZV lacks viral thymidine kinase entirely
C) Acyclovir is not absorbed at the lower dose
D) VZV replicates in the bloodstream where drug levels are lower
E) VZV uses a different DNA polymerase that acyclovir cannot reach
ANSWER: A
Rationale:
VZV is approximately 10-fold less susceptible to acyclovir than HSV-1 and HSV-2, with correspondingly higher inhibitory concentrations required for clinical effect. This reduced susceptibility is why varicella and zoster require substantially higher acyclovir doses (e.g., 800 mg five times daily) than HSV infections (e.g., 400 mg three times daily).
Option B: Option B is incorrect: VZV does possess a viral thymidine kinase and can activate acyclovir; it is simply less susceptible than HSV. The virus that lacks viral TK is CMV.
Option C: Option C is incorrect: the higher dosing reflects reduced viral susceptibility, not a failure of absorption at lower doses.
Option D: Option D is incorrect: the dose difference is driven by intrinsic VZV susceptibility, not by a special bloodstream replication compartment.
Option E: Option E is incorrect: VZV does not use a fundamentally different, acyclovir-inaccessible polymerase; the relevant difference is its lower susceptibility, not an unreachable enzyme.
3. Ganciclovir is structurally related to acyclovir but differs in one key feature of its acyclic side chain, which alters how it behaves once incorporated into viral DNA. What structural distinction sets ganciclovir apart from acyclovir, and what is its consequence?
A) Ganciclovir lacks any sugar moiety, so it cannot be incorporated into DNA
B) Ganciclovir carries an extra phosphate, making it active without any kinase
C) Ganciclovir is a pyrophosphate analogue rather than a nucleoside analogue
D) Ganciclovir contains a ribose ring identical to natural guanosine
E) Ganciclovir possesses a 3'-hydroxyl group on its acyclic side chain, making it a less obligate chain terminator than acyclovir
ANSWER: E
Rationale:
Ganciclovir possesses a 3'-hydroxyl group on its acyclic side chain that acyclovir lacks. Because chain elongation requires a free 3'-hydroxyl, this feature permits some degree of chain elongation after ganciclovir is incorporated, making it a less obligate chain terminator than acyclovir, though it still slows and ultimately halts viral DNA synthesis.
Option A: Option A is incorrect: ganciclovir does have an acyclic sugar-like side chain and is incorporated into DNA; it is not excluded from incorporation.
Option B: Option B is incorrect: ganciclovir still requires phosphorylation (initiated by CMV UL97) to become active; it does not carry a built-in activating phosphate.
Option C: Option C is incorrect: ganciclovir is a nucleoside analogue, not a pyrophosphate analogue; the pyrophosphate analogue is foscarnet.
Option D: Option D is incorrect: ganciclovir has an acyclic side chain, not a complete ribose ring identical to natural guanosine.
4. Foscarnet differs from the nucleoside and nucleotide analogues in both its activation requirement and its precise site of action on the viral DNA polymerase. Which statement correctly describes foscarnet's mechanism?
A) It requires viral thymidine kinase for activation, then terminates the DNA chain
B) It binds directly to the pyrophosphate-binding site of viral DNA polymerase, blocking pyrophosphate release, and requires no intracellular phosphorylation
C) It is activated by CMV UL97 phosphotransferase before inhibiting the polymerase
D) It inhibits viral neuraminidase, preventing virion release
E) It is incorporated into viral DNA and causes obligate chain termination via a missing 3'-hydroxyl
ANSWER: B
Rationale:
Foscarnet (phosphonoformic acid) binds directly to the pyrophosphate-binding site of the viral DNA polymerase, blocking the release of pyrophosphate during nucleotide incorporation and thereby halting chain elongation. Because it acts directly on the enzyme, it requires no intracellular phosphorylation, which is why it remains active against TK-deficient acyclovir-resistant HSV and UL97-mutant ganciclovir-resistant CMV.
Option A: Option A is incorrect: foscarnet does not require viral thymidine kinase and is not a chain-terminating nucleoside analogue; that description fits acyclovir.
Option C: Option C is incorrect: foscarnet does not depend on UL97 activation; that activation step applies to ganciclovir.
Option D: Option D is incorrect: foscarnet does not inhibit neuraminidase (an influenza target); it acts on the herpesvirus DNA polymerase.
Option E: Option E is incorrect: incorporation into DNA with chain termination from a missing 3'-hydroxyl describes acyclovir, not foscarnet, which is a non-incorporated pyrophosphate analogue.
5. Cidofovir is an acyclic nucleoside phosphonate whose activation pathway distinguishes it from acyclovir and ganciclovir and explains its unusually broad antiviral spectrum. Which statement best characterizes cidofovir's activation and the resulting spectrum?
A) It is activated by viral thymidine kinase, limiting it to HSV and VZV
B) It is activated by CMV UL97, limiting it to CMV only
C) It requires no activation and acts directly on the polymerase pyrophosphate site
D) Cellular enzymes convert it directly to cidofovir diphosphate independent of viral kinases, giving broad activity across multiple DNA virus families
E) It is activated only inside orthopoxvirus-infected cells
ANSWER: D
Rationale:
Cidofovir contains a phosphonate group that mimics a nucleoside monophosphate, so cellular enzymes convert it directly to cidofovir diphosphate without any viral kinase. Because activation is virus-independent, cidofovir retains activity against TK-deficient acyclovir-resistant HSV and UL97-mutant ganciclovir-resistant CMV, and its spectrum is broad — encompassing CMV, HSV-1, HSV-2, VZV, adenovirus, BK polyomavirus, and orthopoxviruses.
Option A: Option A is incorrect: cidofovir does not require viral thymidine kinase, so it is not limited to HSV and VZV.
Option B: Option B is incorrect: cidofovir does not depend on CMV UL97 and is not limited to CMV.
Option C: Option C is incorrect: cidofovir does require cellular phosphorylation to its diphosphate; the agent that needs no activation and acts on the pyrophosphate site is foscarnet.
Option E: Option E is incorrect: cidofovir activation occurs in host cells generally and is not restricted to orthopoxvirus-infected cells, although orthopoxviruses are within its spectrum.
6. A patient is to receive intravenous acyclovir for HSV encephalitis. Although acyclovir is well tolerated overall, a specific renal adverse effect can occur under certain infusion conditions and is preventable. Which adverse effect, and what is the key preventive measure?
A) Crystalline nephropathy from tubular precipitation of acyclovir; prevent with adequate hydration and avoiding rapid infusion
B) Severe hypocalcemia from drug-induced cation chelation; prevent with calcium loading
C) Irreversible proximal tubular necrosis via OAT1 uptake; prevent with probenecid
D) Myelosuppression; prevent with granulocyte colony-stimulating factor
E) Genital ulceration from urinary drug; prevent with topical care
ANSWER: A
Rationale:
Intravenous acyclovir can precipitate in the renal tubules, producing a crystalline nephropathy, particularly when infused rapidly or in hypovolemic patients. The key preventive measures are adequate hydration during infusion and avoiding overly rapid administration, which keep the drug in solution and protect renal function.
Option B: Option B is incorrect: hypocalcemia from divalent-cation chelation is characteristic of foscarnet, not acyclovir.
Option C: Option C is incorrect: OAT1-mediated proximal tubular toxicity managed with probenecid describes cidofovir, not acyclovir.
Option D: Option D is incorrect: dose-limiting myelosuppression managed with G-CSF is a feature of ganciclovir, not acyclovir.
Option E: Option E is incorrect: genital ulceration from high urinary drug concentration is a distinctive foscarnet effect, not an acyclovir effect.
7. Oral acyclovir has poor (roughly 15% to 30%) and saturable bioavailability. Valacyclovir was developed specifically to overcome this limitation. Compared with equivalent oral acyclovir doses, what plasma acyclovir exposure does valacyclovir achieve, and by what mechanism?
A) Identical exposure, because valacyclovir is simply acyclovir under another name
B) Lower exposure, because valacyclovir is poorly absorbed
C) Plasma acyclovir concentrations three to five times higher, because valacyclovir is rapidly hydrolyzed to acyclovir after efficient oral absorption
D) Higher exposure, because valacyclovir resists renal excretion
E) Higher exposure, because valacyclovir is not converted to acyclovir at all
ANSWER: C
Rationale:
Valacyclovir is the L-valyl ester prodrug of acyclovir. It is efficiently absorbed and then rapidly hydrolyzed by intestinal and hepatic valacyclohydrolase to acyclovir, achieving plasma acyclovir concentrations three to five times higher than equivalent oral acyclovir doses and approximating intravenous acyclovir exposure. This is why valacyclovir is favored for outpatient HSV and VZV therapy.
Option A: Option A is incorrect: valacyclovir is a distinct prodrug, not merely another name for acyclovir; its purpose is to raise systemic acyclovir exposure.
Option B: Option B is incorrect: valacyclovir is well absorbed, which is precisely the advantage over poorly bioavailable oral acyclovir.
Option D: Option D is incorrect: the exposure advantage comes from improved absorption and conversion to acyclovir, not from resisting renal excretion.
Option E: Option E is incorrect: valacyclovir must be converted to acyclovir to be active; the claim that it is not converted is false.
8. In CMV, resistance can arise from mutations in two distinct viral genes, and the resistance pattern depends on which gene is affected. Which statement correctly describes the relationship between UL97 and UL54 mutations and cross-resistance among CMV antivirals?
A) UL97 mutations confer resistance to foscarnet but not ganciclovir
B) UL54 mutations affect only foscarnet and never ganciclovir or cidofovir
C) UL97 and UL54 mutations both selectively spare cidofovir under all circumstances
D) UL97 mutations cause resistance to all CMV antivirals simultaneously
E) UL54 (polymerase) mutations can confer cross-resistance involving ganciclovir and foscarnet, and combined UL97 plus UL54 mutations produce high-level multidrug resistance
ANSWER: E
Rationale:
UL97 encodes the phosphotransferase that activates ganciclovir, so UL97 mutations cause ganciclovir resistance while foscarnet (which acts directly on the polymerase) generally remains active. UL54 encodes the DNA polymerase itself; UL54 mutations can confer cross-resistance involving ganciclovir and foscarnet and may affect cidofovir as well. When UL97 and UL54 mutations occur together, the result is high-level multidrug resistance that can leave cidofovir or combination therapy as the only options.
Option A: Option A is incorrect: UL97 mutations cause ganciclovir resistance, not foscarnet resistance; foscarnet usually retains activity against UL97-mutant strains.
Option B: Option B is incorrect: UL54 polymerase mutations can affect ganciclovir and cidofovir as well, not foscarnet alone.
Option C: Option C is incorrect: cidofovir is not universally spared; UL54 mutations can confer cross-resistance that includes cidofovir.
Option D: Option D is incorrect: a UL97 mutation alone does not confer resistance to all CMV antivirals; foscarnet typically still works.
9. Cidofovir administration requires a strict mandatory protocol with every dose. Which combination of measures constitutes that protocol, and what is its purpose?
A) Calcium and magnesium repletion before each dose to prevent chelation-induced hypocalcemia
B) Oral probenecid before and after the dose, intravenous saline preloading, and checking serum creatinine and urine protein, all to mitigate OAT1-mediated proximal tubular nephrotoxicity
C) Twice-weekly complete blood counts and G-CSF support to prevent neutropenia
D) Rapid infusion without hydration to shorten tubular exposure
E) Co-administration with acyclovir to broaden coverage
ANSWER: B
Rationale:
Cidofovir is concentrated in proximal tubular cells by the organic anion transporter 1 (OAT1), producing dose-dependent nephrotoxicity. The mandatory protocol mitigates this: oral probenecid (a competitive OAT1 inhibitor) is given before and after each dose, intravenous saline preloading is required, and serum creatinine and urine protein are checked, with the drug withheld for a creatinine rise of 0.3 mg/dL or proteinuria of 2+ or greater.
Option A: Option A is incorrect: calcium and magnesium repletion addresses foscarnet's cation chelation, not cidofovir nephrotoxicity.
Option C: Option C is incorrect: CBC monitoring and G-CSF support relate to ganciclovir myelosuppression, not the cidofovir protocol.
Option D: Option D is incorrect: rapid infusion without hydration would worsen, not prevent, nephrotoxicity; saline preloading is required.
Option E: Option E is incorrect: cidofovir is not routinely co-administered with acyclovir for coverage; its protocol centers on probenecid and hydration to protect the kidney.
10. Intravenous acyclovir is the treatment of choice for herpes simplex encephalitis. Which pharmacokinetic property of acyclovir makes it suitable for this central nervous system infection?
A) It is highly protein-bound and remains confined to plasma
B) It is actively excluded from the cerebrospinal fluid by efflux transporters
C) It requires intrathecal administration because it cannot enter the brain
D) It distributes widely and achieves cerebrospinal fluid concentrations approximately 50% of plasma levels
E) It concentrates in the cerebrospinal fluid to ten times the plasma level
ANSWER: D
Rationale:
Acyclovir distributes widely and achieves cerebrospinal fluid (CSF) concentrations approximately 50% of plasma levels. This adequate central nervous system penetration is what makes intravenous acyclovir effective for herpes simplex encephalitis, where the virus is replicating within the brain.
Option A: Option A is incorrect: acyclovir is not highly protein-bound and does reach the CSF; it is not confined to plasma.
Option B: Option B is incorrect: acyclovir is not actively excluded from the CSF; it penetrates to roughly half the plasma concentration.
Option C: Option C is incorrect: acyclovir does not require intrathecal dosing; intravenous administration achieves therapeutic CSF levels.
Option E: Option E is incorrect: acyclovir does not concentrate to tenfold plasma levels in CSF; its CSF level is about 50% of plasma.
11. Ganciclovir is considerably more toxic than acyclovir, and this difference is explained by the relative selectivity of each drug for infected cells. Compared with acyclovir's selectivity for HSV-infected cells, how does ganciclovir's selectivity for CMV-infected cells compare, and what is the consequence?
A) Ganciclovir's selectivity is considerably lower — the UL97 phosphotransferase concentrates ganciclovir triphosphate only about 10-fold in CMV-infected cells — which underlies its more significant toxicity
B) Ganciclovir's selectivity is far greater than acyclovir's, yet it is paradoxically more toxic
C) Ganciclovir and acyclovir have identical selectivity indices
D) Ganciclovir is entirely nonselective because it is activated only by host kinases
E) Ganciclovir's selectivity depends on viral thymidine kinase just as acyclovir's does
ANSWER: A
Rationale:
The selectivity of ganciclovir for CMV-infected cells is considerably lower than that of acyclovir for HSV-infected cells. The CMV UL97 phosphotransferase concentrates ganciclovir triphosphate in infected cells by only about 10-fold, compared with the roughly 40- to 100-fold gradient acyclovir achieves in HSV-infected cells. This narrower selectivity index underlies ganciclovir's more significant toxicity, particularly its dose-limiting myelosuppression.
Option B: Option B is incorrect: ganciclovir's selectivity is lower, not greater, than acyclovir's; the lower selectivity is exactly why it is more toxic.
Option C: Option C is incorrect: the selectivity indices are not identical; ganciclovir's is substantially narrower.
Option D: Option D is incorrect: ganciclovir is not entirely nonselective and is not activated only by host kinases — its first activation step is performed by the viral UL97 enzyme.
Option E: Option E is incorrect: ganciclovir activation in CMV depends on UL97, not on viral thymidine kinase (which CMV lacks).
12. Brincidofovir (CMX001) is a lipid conjugate of cidofovir with a distinct cellular entry route and a specific approved indication. Which statement correctly pairs brincidofovir's cellular entry mechanism with its U.S. Food and Drug Administration (FDA)-approved indication?
A) It enters cells via OAT1 and is approved for CMV retinitis
B) It requires viral thymidine kinase for uptake and is approved for genital herpes
C) It enters cells via lipid transport pathways rather than OAT1, and is FDA-approved (2021, as Tembexa) for the treatment of smallpox
D) It is actively transported by UL97 and is approved for influenza
E) It enters cells by passive diffusion only and is approved for hepatitis C
ANSWER: C
Rationale:
Brincidofovir is a lipid (ether-linked) conjugate of cidofovir that enters cells through lipid transport pathways rather than via the organic anion transporter 1 (OAT1); this bypass of OAT1 dramatically reduces proximal tubular exposure and nephrotoxicity. It received FDA approval in June 2021 under the brand name Tembexa for the treatment of smallpox (variola) as part of strategic national stockpile preparedness.
Option A: Option A is incorrect: brincidofovir specifically avoids OAT1 entry, and its approved indication is smallpox, not CMV retinitis.
Option B: Option B is incorrect: brincidofovir does not require viral thymidine kinase, and it is not approved for genital herpes.
Option D: Option D is incorrect: brincidofovir is not transported by UL97 and has no influenza indication.
Option E: Option E is incorrect: its defining feature is lipid-pathway entry (not passive diffusion only), and it is approved for smallpox, not hepatitis C.
13. Letermovir is mechanistically distinct from the other CMV antivirals and has a specific prophylactic role. Which set of properties correctly characterizes letermovir?
A) DNA polymerase inhibitor; dose-limiting nephrotoxicity; treatment of CMV retinitis
B) CMV terminase (UL56) inhibitor; lacks myelosuppression; approved for CMV prophylaxis in seropositive hematopoietic stem cell transplant recipients
C) Pyrophosphate analogue; severe hypocalcemia; salvage therapy for resistant HSV
D) Acyclic nucleoside phosphonate; OAT1 nephrotoxicity; broad DNA virus coverage
Letermovir inhibits the CMV terminase complex by targeting its UL56 subunit, a mechanism entirely distinct from the DNA polymerase inhibitors, so it has no cross-resistance with ganciclovir, foscarnet, or cidofovir. It lacks myelosuppression and has favorable oral bioavailability, and it was approved in 2017 for CMV prophylaxis in CMV-seropositive hematopoietic stem cell transplant (HSCT) recipients.
Option A: Option A is incorrect: letermovir is not a DNA polymerase inhibitor and is not used to treat CMV retinitis; its role is prophylaxis.
Option C: Option C is incorrect: the pyrophosphate analogue with hypocalcemia used as HSV salvage is foscarnet, not letermovir.
Option D: Option D is incorrect: the acyclic nucleoside phosphonate with OAT1 nephrotoxicity and broad coverage is cidofovir, not letermovir.
Option E: Option E is incorrect: letermovir is not a neuraminidase inhibitor and has no influenza indication.
14. Beyond its dose-dependent nephrotoxicity, cidofovir has a distinctive non-renal adverse effect reported primarily in HIV patients receiving systemic therapy. Which adverse effect is characteristic of cidofovir in this setting?
A) Genital ulceration from high urinary drug concentration
B) Dose-limiting neutropenia
C) Severe hypomagnesemia from cation chelation
D) Crystalline nephropathy preventable by hydration alone
E) Uveitis and ocular hypotony
ANSWER: E
Rationale:
Uveitis and ocular hypotony are distinctive adverse effects of cidofovir, reported primarily in HIV patients receiving systemic cidofovir. These ocular effects are recognized complications separate from the drug's principal dose-limiting nephrotoxicity.
Option A: Option A is incorrect: genital ulceration from high urinary drug concentration is a distinctive foscarnet effect, not a cidofovir effect.
Option B: Option B is incorrect: dose-limiting neutropenia characterizes ganciclovir, not cidofovir.
Option C: Option C is incorrect: severe electrolyte disturbances from divalent-cation chelation, such as hypomagnesemia, are characteristic of foscarnet.
Option D: Option D is incorrect: crystalline nephropathy preventable by hydration describes intravenous acyclovir; cidofovir nephrotoxicity is OAT1-mediated and requires probenecid plus saline, and the question asks for the distinctive ocular effect.
15. In addition to nephrotoxicity and electrolyte disturbances, foscarnet has a distinctive localized adverse effect related to its excretion in urine. Which adverse effect is characteristic of foscarnet, and how is it managed?
A) Uveitis and ocular hypotony; managed with topical corticosteroids
B) Neutropenia; managed with granulocyte colony-stimulating factor
C) Hepatotoxicity; managed by monitoring transaminases
D) Genital ulceration from high foscarnet concentrations in urine; managed by maintaining adequate urine output and genital hygiene
E) Pulmonary fibrosis; managed by drug discontinuation
ANSWER: D
Rationale:
Genital ulceration is a distinctive adverse effect of foscarnet, caused by high concentrations of the drug in urine contacting genital epithelium. It is managed by maintaining adequate urine output and attention to genital hygiene. This is separate from foscarnet's major toxicities of nephrotoxicity and divalent-cation electrolyte disturbances.
Option A: Option A is incorrect: uveitis and ocular hypotony are characteristic of cidofovir in HIV patients, not foscarnet.
Option B: Option B is incorrect: dose-limiting neutropenia managed with G-CSF is a ganciclovir effect; foscarnet notably lacks myelosuppression.
Option C: Option C is incorrect: prominent hepatotoxicity is more associated with brincidofovir; it is not the distinctive foscarnet effect described.
Option E: Option E is incorrect: pulmonary fibrosis is not a recognized characteristic adverse effect of foscarnet.
16. Two validated strategies exist to prevent CMV disease after solid organ transplant: universal prophylaxis and pre-emptive therapy. Which statement correctly distinguishes them and identifies a recognized limitation of universal prophylaxis?
A) Pre-emptive therapy gives antivirals to every patient regardless of viral load, whereas universal prophylaxis simply waits for symptoms to appear
B) Pre-emptive therapy requires no viral load monitoring of any kind and is started only after end-organ disease develops
C) Universal prophylaxis treats all patients above a risk threshold for a defined period and reduces CMV disease more consistently, but is associated with late-onset CMV disease after prophylaxis is discontinued
D) Universal prophylaxis eliminates any possibility of CMV disease at every time point after transplant
E) Universal prophylaxis and pre-emptive therapy are identical in both approach and outcome
ANSWER: C
Rationale:
Universal prophylaxis gives antiviral therapy (valganciclovir or ganciclovir) to all patients above a defined risk threshold for a set period after transplant and reduces CMV disease incidence more consistently; its recognized drawback is late-onset CMV disease occurring after prophylaxis is stopped, particularly in CMV-seropositive-donor/seronegative-recipient (D+/R-) patients whose immune reconstitution may be incomplete. Pre-emptive therapy instead monitors CMV viral load by polymerase chain reaction (PCR) and initiates treatment when a predefined threshold is crossed, before symptoms develop.
Option A: Option A is incorrect: it reverses the definitions — pre-emptive therapy is viral-load-triggered (not given to everyone), and universal prophylaxis treats broadly rather than waiting for symptoms.
Option B: Option B is incorrect: pre-emptive therapy fundamentally depends on regular viral load monitoring and is started before symptoms, not after end-organ disease.
Option D: Option D is incorrect: universal prophylaxis does not eliminate all CMV disease; late-onset disease occurs after it ends.
Option E: Option E is incorrect: the two strategies differ substantially in approach and in their characteristic patterns of breakthrough disease.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.